Elixirgen Scientific, Inc. is pleased to announce the opening of a new Japanese office located in Kawasaki city, Kanagawa Prefecture. The Japan office will allow Elixirgen Scientific to support a growing demand for induced pluripotent stem cell (iPSC) differentiation technologies in Japan and throughout the Asia/Pacific region. This is an important milestone as it is the company’s first expansion outside of the headquarters in Baltimore, Maryland, USA.
With the opening of the Japan office, Elixirgen Scientific will also deepen the collaboration with Ricoh Co., Ltd., a joint business development partner and investor headquartered in Japan. By combining Ricoh's bioprinting technology and Elixirgen Scientific's iPSC differentiation technology, the two companies plan to soon commercialize multi-electrode array (MEA) plates pre-seeded with human iPSC-derived neurons. These ready-to-use bioprinted neuron-MEA plates will require less cells than traditional methods without sacrificing batch-to-batch consistency or reproducibility, which will be vital for high-throughput applications such as drug discovery and toxicity screening.